Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
出版年份 2022 全文链接
标题
Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
作者
关键词
-
出版物
Frontiers in Immunology
Volume 13, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-09-02
DOI
10.3389/fimmu.2022.991092
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
- (2022) Adam D. Cohen et al. Blood Cancer Journal
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR T-cell therapy in multiple myeloma: more room for improvement
- (2021) Phaik Ju Teoh et al. Blood Cancer Journal
- Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma
- (2021) Tom Martin et al. CURRENT MEDICAL RESEARCH AND OPINION
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
- (2021) Sundar Jagannath et al. Blood Cancer Journal
- Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2
- (2021) Yael C. Cohen et al. BLOOD
- Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma
- (2021) Thomas Martin et al. BLOOD
- OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
- (2021) Larry D. Anderson et al. Clinical Lymphoma Myeloma & Leukemia
- Development of CAR-T cell therapies for multiple myeloma
- (2020) Nico Gagelmann et al. LEUKEMIA
- B-cell maturation antigen expression across hematologic cancers: a systematic literature review
- (2020) Ahmet Dogan et al. Blood Cancer Journal
- CAR-T design: Elements and their synergistic function
- (2020) Jayapriya Jayaraman et al. EBioMedicine
- Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
- (2020) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
- (2020) Gils Roex et al. Journal of Hematology & Oncology
- Engineering and Design of Chimeric Antigen Receptors
- (2019) Sonia Guedan et al. Molecular Therapy-Methods & Clinical Development
- Chimeric Antigen Receptor–Engineered T Cell Therapy in Lymphoma
- (2019) Paolo Strati et al. Current Oncology Reports
- T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
- (2019) Smita S. Chandran et al. IMMUNOLOGICAL REVIEWS
- Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
- (2019) Marijke Timmers et al. Frontiers in Immunology
- Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide
- (2019) Melissa Works et al. MOLECULAR CANCER THERAPEUTICS
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- CARs and other T cell therapies for MM: The clinical experience
- (2018) Sophia Danhof et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- CAR T-cell Therapy: A New Era in Cancer Immunotherapy
- (2018) Miliotou N. Androulla et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials
- (2018) Naveen Mangal et al. HEMATOLOGICAL ONCOLOGY
- Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
- (2018) Kevin M. Friedman et al. HUMAN GENE THERAPY
- Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)
- (2018) Bianca D. Santomasso et al. Cancer Discovery
- Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
- (2018) Shih-Feng Cho et al. Frontiers in Immunology
- Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy
- (2018) Noelle Frey et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- Adoptive cellular therapies: the current landscape
- (2018) Maartje W. Rohaan et al. VIRCHOWS ARCHIV
- Chimeric antigen receptor T-cell therapies for lymphoma
- (2017) Jennifer N. Brudno et al. Nature Reviews Clinical Oncology
- Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma
- (2017) Nikhil C. Munshi et al. JAMA Oncology
- APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
- (2016) Y.-T. Tai et al. BLOOD
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- (2016) Michael Ghermezi et al. HAEMATOLOGICA
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- (2016) Michael Ghermezi et al. HAEMATOLOGICA
- Toxicity and management in CAR T-cell therapy
- (2016) Challice L Bonifant et al. Molecular Therapy-Oncolytics
- Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy
- (2015) Xiang-Jun Tang et al. Oncotarget
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Lung Cancer Screening
- (2015) Douglas E. Wood Thoracic Surgery Clinics
- The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
- (2014) M. Hudecek et al. Cancer Immunology Research
- Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors
- (2014) Chuan Jin et al. Molecular Therapy-Methods & Clinical Development
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- Design and development of therapies using chimeric antigen receptor-expressing T cells
- (2013) Gianpietro Dotti et al. IMMUNOLOGICAL REVIEWS
- IMWG consensus on risk stratification in multiple myeloma
- (2013) W J Chng et al. LEUKEMIA
- IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
- (2008) C. S. Hinrichs et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search